Back to discover
Drug

Bromocriptine

Regulatory activity · MHRA
Emerging researchLate-stage development
Also known as 2-Bromo-alpha-ergocryptine, 2-Bromo-alpha-ergokryptin, 2-Bromo-alpha-ergokryptine, 2-br-alpha-ergocryptine+10 more

2-Bromo-alpha-ergocryptine, 2-Bromo-alpha-ergokryptin, 2-Bromo-alpha-ergokryptine, 2-br-alpha-ergocryptine, 2-bromoergocryptine, Brom-ergocryptine, Bromoergocriptine, Bromoergocryptine, Cycloset, Parlodel, Bromocriptina, Bromocryptine, Bromocriptine Mesylate, Bromocriptinum.

RxNorm1760ChEMBLCHEMBL493UNII3A64E3G5ZO
1
Research papers
3
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Prediabetes

Clinical trial2026-07-31Primary completion · ClinicalTrials.gov

Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

A Randomized, Double-blind, Double-dummy, Positive Controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets in Female Patients With Hyperprolactinemia

Clinical trial2025-10-02Results expected Q4 2026 · ClinicalTrials.gov

Toward Understanding Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

Clinical trial2025-04-11Results posted · ClinicalTrials.gov

Drug Safety Update: Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation

Regulatory2024-10-24MHRA

Dopamine Action on Metabolism Depending on Genetic Heterogeneity - a Randomized, Placebo-controlled Double Blind Study

Clinical trial2024-08-14Completed · ClinicalTrials.gov

The Role of Dopamine in Fronto-striatal Activation in Emotional-motivational Pain Processing in Patients With Chronic Pain

Clinical trial2023-07-31Completed · ClinicalTrials.gov

Bromocriptine in the Treatment of Peripartum Cardiomyopathy, A Bayesian Randomized Registry Trial

Clinical trial2023-01-01Withdrawn · ClinicalTrials.gov

Satisfaction of Patients With the Chosen Method of Inhibition of Lactation: With the Use of Drugs Lowering the Level of Prolactin or Without the Use of Pharmacological Agents in Postnatal Period, Taking Into Account Individual Conditions

Clinical trial2022-07-01Primary completion · ClinicalTrials.gov

Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

Clinical trial2021-12-10Results posted · ClinicalTrials.gov

Bromocriptine Quick Release (QR) as Adjunct Therapy in Type 1 Diabetes

Clinical trial2021-09-13Results posted · ClinicalTrials.gov

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.

Research2010-03-23Diabetes care

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Bromocriptine
Aliases & brands
2-Bromo-alpha-ergocryptine2-Bromo-alpha-ergokryptin2-Bromo-alpha-ergokryptine2-br-alpha-ergocryptine2-bromoergocryptineBrom-ergocryptineBromoergocriptineBromoergocryptineCyclosetParlodelBromocriptinaBromocryptineBromocriptine MesylateBromocriptinum
RxNorm CUI
1760
ChEMBL ID
CHEMBL493
UNII
3A64E3G5ZO
Regulatory jurisdictions
mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
1
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2024-10-24Safety communicationSafety
Drug Safety Update: Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

29 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
29
registered trials across all phases
LATEST COMPLETION 2025
3
Active studies
3
Recruiting
19
Late-stage (III+)
16
Completed
10
Discontinued
PHASE DISTRIBUTIONn = 29
Early Phase 11Phase 11Phase 1 / 22Phase 26Phase 37Phase 47Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)

RecruitingPH IVDennis M. McNamara, MD, MSn=2502028

Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Prediabetes

Not yet recruitingPH IVVA Pittsburgh Healthcare Systemn=152026

Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

CompletedPH IVEastern Virginia Medical Schooln=842018

Effect of Cycloset on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled on GLP-1 Analogue Therapy

CompletedPH IVThe University of Texas Health Science Center at San Antonion=232018

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

WithdrawnPH IVUniversity of California, Berkeley2018

Recent completions

Trials that read out recently, adding to the completed evidence base.

Toward Understanding Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

CompletedPH IUniversity of California, San Diegon=312025

Dopamine Action on Metabolism Depending on Genetic Heterogeneity - a Randomized, Placebo-controlled Double Blind Study

CompletedPH IIUniversity Hospital Tuebingenn=1202024

The Role of Dopamine in Fronto-striatal Activation in Emotional-motivational Pain Processing in Patients With Chronic Pain

CompletedN/Asusanne beckern=482023

Pathophysiology and Nature of Ovarian Hyperstimulation Syndrome (OHSS) as a Clinical Entity Could be Fully Explained and Effectively Managed as a State of Defective Mineralocorticoid Response

CompletedPH IIGanin Fertility Centern=1072020

Efficacy of Bromocriptine to Reduce Body Temperature in Febrile Critically-ill Adults With Acute Neurologic Disease: an Open-label, Blinded Endpoint, Randomized Controlled Trial

CompletedPH I/IIUniversity of California, San Franciscon=472019

Bromocriptine Quick Release (QR) as Adjunct Therapy in Type 1 Diabetes

CompletedPH IIUniversity of Colorado, Denvern=1082019

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • Diabetes care1
Leading researchers
  • Cincotta AH1
  • Ezrokhi M1
  • Gaziano JM1
  • Ma ZJ1
  • O'Connor CM1
  • Rutty D1
  • Scranton RE1
Leading institutions
free-text, unnormalised
  • Massachusetts Veterans Epidemiology Research and Information Center/VA Cooperative Studies Programs1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.